| The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, ... Science 359 (6371), 104-108, 2018 | 2796 | 2018 |
| Targeted agents and immunotherapies: optimizing outcomes in melanoma JJ Luke, KT Flaherty, A Ribas, GV Long Nature reviews Clinical oncology 14 (8), 463-482, 2017 | 1275 | 2017 |
| Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ... Journal of Clinical Oncology 34 (26), 3119-3125, 2016 | 934 | 2016 |
| Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA GR Oxnard, CP Paweletz, Y Kuang, SL Mach, A O'Connell, MM Messineo, ... Clinical cancer research 20 (6), 1698-1705, 2014 | 877 | 2014 |
| Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin FS Hodi, CL Corless, A Giobbie-Hurder, JA Fletcher, M Zhu, ... Journal of clinical oncology 31 (26), 3182-3190, 2013 | 722 | 2013 |
| WNT/β-catenin pathway activation correlates with immune exclusion across human cancers JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski Clinical Cancer Research 25 (10), 3074-3083, 2019 | 592 | 2019 |
| Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ... Journal of Clinical Oncology 36 (16), 1611-1618, 2018 | 561 | 2018 |
| Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy L Heinzerling, PA Ott, FS Hodi, AN Husain, A Tajmir-Riahi, H Tawbi, ... Journal for immunotherapy of cancer 4, 1-11, 2016 | 554 | 2016 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 438 | 2022 |
| Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma S Spranger, JJ Luke, R Bao, Y Zha, KM Hernandez, Y Li, AP Gajewski, ... Proceedings of the National Academy of Sciences 113 (48), E7759-E7768, 2016 | 405 | 2016 |
| T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection JA Trujillo, RF Sweis, R Bao, JJ Luke Cancer immunology research 6 (9), 990-1000, 2018 | 386 | 2018 |
| Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis BW Labadie, R Bao, JJ Luke Clinical Cancer Research 25 (5), 1462-1471, 2019 | 366 | 2019 |
| Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037) TC Mitchell, O Hamid, DC Smith, TM Bauer, JS Wasser, AJ Olszanski, ... Journal of Clinical Oncology 36 (32), 3223-3230, 2018 | 349 | 2018 |
| Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, ... Cancer cell 38 (4), 500-515. e3, 2020 | 339 | 2020 |
| The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma AN Shoushtari, RR Munhoz, D Kuk, PA Ott, DB Johnson, KK Tsai, ... Cancer 122 (21), 3354-3362, 2016 | 303 | 2016 |
| STING agonists as cancer therapeutics A Amouzegar, M Chelvanambi, JN Filderman, WJ Storkus, JJ Luke Cancers 13 (11), 2695, 2021 | 299 | 2021 |
| Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study L Min, FS Hodi, A Giobbie-Hurder, PA Ott, JJ Luke, H Donahue, M Davis, ... Clinical Cancer Research 21 (4), 749-755, 2015 | 295 | 2015 |
| STING pathway agonism as a cancer therapeutic BA Flood, EF Higgs, S Li, JJ Luke, TF Gajewski Immunological reviews 290 (1), 24-38, 2019 | 289 | 2019 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 280 | 2020 |
| Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study JS Weber, MS Carlino, A Khattak, T Meniawy, G Ansstas, MH Taylor, ... The Lancet 403 (10427), 632-644, 2024 | 235 | 2024 |
Riyue BaoAssociate Professor, UPitt Medicine; Co-Director Bioinformatics, UPMC Hillman Cancer Center確認したメール アドレス: pitt.edu